Price movement over the last 24 hours
Abbott Laboratories vs IONQ Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while IONQ Inc trades at $45.17 (market cap $16.93B). The key difference: Abbott Laboratories is far larger — about 9.9× IONQ Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| ABT | IONQ | |
|---|---|---|
Market Cap | $166.94B | $16.93B |
Sector | Health | Technology |
52-Week High | $136.62 | $82.09 |
52-Week Low | $82.57 | $26.59 |
Enterprise Value | $193.69B | $14.93B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
IONQ trades at $48.87, down 0.51% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth with $130.02 million in 2025 and a projected $187 million in 2026, but remains unprofitable with a net loss of $510.38 million in 2025. Recent news highlights its leadership in quantum computing technology and expansion into cybersecurity and space applications, though cash burn remains a concern.
The outlook for IONQ is mixed; analyst consensus is split evenly between Buy and Hold with a $73.75 price target suggesting 51% upside. Key opportunities include technological advantages and commercial partnerships, while risks involve high cash burn, intense competition, and the speculative nature of quantum computing commercialization. Investors should weigh growth potential against financial sustainability.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →